NASDAQ: AVBP

Arrivent Biopharma Inc Stock Forecast, Predictions & Price Target

The consensus among 3 Wall Street analysts covering (NASDAQ: AVBP) stock is to Strong Buy AVBP stock.

Out of 3 analysts, 3 (100%) are recommending AVBP as a Strong Buy, 0 (0%) are recommending AVBP as a Buy, 0 (0%) are recommending AVBP as a Hold, 0 (0%) are recommending AVBP as a Sell, and 0 (0%) are recommending AVBP as a Strong Sell.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.

(NASDAQ: AVBP) Arrivent Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.94%.

Arrivent Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast AVBP's revenue for 2026 to be $296,507,350, with the lowest AVBP revenue forecast at $296,507,350, and the highest AVBP revenue forecast at $296,507,350. On average, 1 Wall Street analysts forecast AVBP's revenue for 2027 to be $1,870,747,402, with the lowest AVBP revenue forecast at $1,870,747,402, and the highest AVBP revenue forecast at $1,870,747,402.

In 2028, AVBP is forecast to generate $3,701,756,705 in revenue, with the lowest revenue forecast at $3,701,756,705 and the highest revenue forecast at $3,701,756,705.

According to 3 Wall Street analysts that have issued a 1 year AVBP price target, the average AVBP price target is $30.67, with the highest AVBP stock price forecast at $35.00 and the lowest AVBP stock price forecast at $27.00.

On average, Wall Street analysts predict that Arrivent Biopharma's share price could reach $30.67 by Feb 20, 2025. The average Arrivent Biopharma stock price prediction forecasts a potential upside of 98.62% from the current AVBP share price of $15.44.

(NASDAQ: AVBP) forecast ROE is N/A, which is considered weak.